Curve Therapeutics
- 28/02/2024
- Series A
- $51,183,495
Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged.
Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes.
We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.
- Industry Biotechnology Research
- Website https://www.curvetx.com/
- LinkedIn https://www.linkedin.com/company/curve-therapeutics-limited/
Related People
Simon KerryFounder
I am a life-science business professional with 30 years experience of creating and developing innovative companies. Currently, I am the CEO and co-founder of Curve Therapeutics and an Operating Partner at Advent Life Sciences, where I have supported a number of portfolio companies. I also hold non-executive positions at Argonaut Therapeutics and MedCity.
From 2006 to 2017 I was the CEO of Karus Therapeutics, taking the company from start-up to clinical-stage company. Before that, I had a number of Business Development roles at UK and European biotechs, including Ablynx NV, Active Biotech AB, and Isogenica Ltd (Cambridge, UK)
I have held other key commercial appointments at Actinova Ltd (Cambridge UK), and Actigen Ltd (Cambridge, UK). He has also occupied senior commercial roles at the Health Protection Agency (Salisbury, UK) and within the Jasmin group of companies.
I hold a degree in Medicinal Chemistry, a life science PhD and an executive MBA from Loughborough University Business School.